Screener
Pacific Biosciences of California PACB Acquisition and integration costs
Discontinued — last reported Q4 '25
Acquisition and integration costs at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationAcquisitionRelatedCosts.
The source filing: Pacific Biosciences of California’s 10-K, filed February 25, 2026.
- Filed
- Feb 25, 2026, 4:03 PM EST
- Fiscal year
- FY2025
- Accession
- 0001299130-26-000034
| (In thousands, except per share amounts) | Years Ended December 31, 2025 | Years Ended December 31, 2024 | Years Ended December 31, 2023 |
|---|---|---|---|
| Research and development | 97,307 | 134,922 | 187,170 |
| Sales, general and administrative | 141,493 | 175,017 | 169,818 |
| Impairment charges | 15,000 | 184,500 | — |
| Merger-related expenses | — | — | 9,042 |
| Amortization of acquired intangible assets | 364,541 | 18,006 | 6,157 |
| Change in fair value of contingent consideration | (18,700) | (850) | 15,060 |
| Total operating expense | 599,641 | 511,595 | 387,247 |
| Operating loss | (553,861) | (474,313) | (334,467) |
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
FAQ
- What is Pacific Biosciences of California's acquisition and integration costs?
- Pacific Biosciences of California (PACB) reported acquisition and integration costs of $0 in Q4 2025.
- What does acquisition and integration costs mean?
- These are the direct costs incurred to identify, evaluate, and integrate acquired businesses into the existing corporate structure. This includes legal fees, consulting expenses, and costs associated with merging operations, systems, and personnel. Investors track these to assess the total capital investment required to execute inorganic growth strategies.
Ask your AI about Pacific Biosciences of California's acquisition and integration costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude